Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs
Conditions
Interventions
Intervention1: αβ T cell depletion: Fludarabine 40 mg/m2/day x 4 days [Days -5 to -2]
Thiotepa 8 mg/Kg IV on Day - 6
Treosulfan 14 G/m2/day x 3 days [days â?? 5 to -3]
Thymoglobulin 1.5 mg/kg/day
Sponsors
Christian Medical College Vellore
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with Class I, II and Class III low risk thalassaemia 2.Adequate cardiac, hepatic and renal function 3.Absence of a matched sibling donor or a matched unrelated donor
Exclusion criteria
Exclusion criteria: 1.Class III high risk thalassaemia 2.Poor cardiac, hepatic or renal functions [ > 4 times ULN]
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the 1 year overall survival in patients undergoing haplo-identical transplantation for Thalassaemia major using a Treosulfan based regimenTimepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To study the incidence of acute and chronic graft versus host disease in patients undergoing Haplo-identical HSCT. 2.To study the pattern of immune reconstitution following Haplo-identical HSCT. 3.To study the risk of infectious complications following haplo-identical HSCT. 4.To study the incidence of primary and secondary graft failure following haplo-identical HSCT.Timepoint: 30days, 60days, 90days, 180days and 360days | — |
Countries
India
Contacts
Public ContactBiju George
Christian Medical College, Vellore
Outcome results
None listed